Literature DB >> 19043140

Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.

Thomas M van Himbergen1, Nirupa R Matthan, Nancy A Resteghini, Seiko Otokozawa, Masumi Ai, Evan A Stein, Peter H Jones, Ernst J Schaefer.   

Abstract

We measured plasma markers of cholesterol synthesis (lathosterol) and absorption (campesterol, sitosterol, and cholestanol) in order to compare the effects of maximal doses of rosuvastatin with atorvastatin and investigate the basis for the significant individual variation in lipid lowering response to statin therapy. Measurements were performed in participants (n = 135) at baseline and after 6 weeks on either rosuvastatin (40 mg/day) or atorvastatin (80 mg/day) therapy. Plasma sterols were measured using gas-liquid chromatography. Rosuvastatin and atorvastatin significantly (P < 0.001) altered plasma total cholesterol (C) levels by -40%, and the ratios of lathosterol/C by -64% and -68%, and campesterol/C by +52% and +72%, respectively, with significant differences (P < 0.001) between the treatment groups for the latter parameter. When using absolute values of these markers, subjects with the greatest reductions in both synthesis (lathosterol) and absorption (campesterol) had significantly greater reductions in total C than subjects in whom the converse was true (-46% versus -34%, P = 0.001), with similar effects for LDL-C. Rosuvastatin and atorvastatin decreased markers of cholesterol synthesis and increased markers of fractional cholesterol absorption, with rosuvastatin having significantly less effect on the latter parameter than atorvastatin. In addition, alterations in absolute values of plasma sterols correlated with the cholesterol lowering response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043140      PMCID: PMC2656667          DOI: 10.1194/jlr.P800042-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  38 in total

1.  Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method.

Authors:  Takuji Kouzuma; Yumiko Uemastu; Tomomi Usami; Shigeyuki Imamura
Journal:  Clin Chim Acta       Date:  2004-08-16       Impact factor: 3.786

2.  Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man.

Authors:  H Vanhanen; Y A Kesäniemi; T A Miettinen
Journal:  Metabolism       Date:  1992-06       Impact factor: 8.694

3.  Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators.

Authors:  T A Miettinen; H Gylling; T Strandberg; S Sarna
Journal:  BMJ       Date:  1998-04-11

4.  Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.

Authors:  R P Naoumova; A D Marais; J Mountney; J C Firth; N B Rendell; G W Taylor; G R Thompson
Journal:  Atherosclerosis       Date:  1996-01-26       Impact factor: 5.162

5.  Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease.

Authors:  Alena Smahelová; Radek Hyspler; Tomás Haas; Alena Tichá; Vladimír Bláha; Zdenĕk Zadák
Journal:  Pharmacol Res       Date:  2005-01       Impact factor: 7.658

6.  Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives.

Authors:  C J Glueck; J Speirs; T Tracy; P Streicher; E Illig; J Vandegrift
Journal:  Metabolism       Date:  1991-08       Impact factor: 8.694

Review 7.  Approaches to measuring cholesterol absorption in humans.

Authors:  Nirupa R Matthan; Alice H Lichtenstein
Journal:  Atherosclerosis       Date:  2004-06       Impact factor: 5.162

8.  Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects.

Authors:  W C Duane
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

9.  Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination.

Authors:  H T Vanhanen; T A Miettinen
Journal:  Atherosclerosis       Date:  1995-06       Impact factor: 5.162

10.  Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum.

Authors:  M I Uusitupa; T A Miettinen; P Happonen; T Ebeling; H Turtola; E Voutilainen; K Pyörälä
Journal:  Arterioscler Thromb       Date:  1992-07
View more
  32 in total

Review 1.  Progress and perspectives in plant sterol and plant stanol research.

Authors:  Peter J H Jones; Maryam Shamloo; Dylan S MacKay; Todd C Rideout; Semone B Myrie; Jogchum Plat; Jean-Baptiste Roullet; David J Baer; Kara L Calkins; Harry R Davis; P Barton Duell; Henry Ginsberg; Helena Gylling; David Jenkins; Dieter Lütjohann; Mohammad Moghadasian; Robert A Moreau; David Mymin; Richard E Ostlund; Rouyanne T Ras; Javier Ochoa Reparaz; Elke A Trautwein; Stephen Turley; Tim Vanmierlo; Oliver Weingärtner
Journal:  Nutr Rev       Date:  2018-10-01       Impact factor: 7.110

2.  Plasma sterol evidence for decreased absorption and increased synthesis of cholesterol in insulin resistance and obesity.

Authors:  Pathmaja Paramsothy; Robert H Knopp; Steven E Kahn; Barbara M Retzlaff; Brian Fish; Lina Ma; Richard E Ostlund
Journal:  Am J Clin Nutr       Date:  2011-09-21       Impact factor: 7.045

3.  Low serum lathosterol levels associate with fatal cardiovascular disease and excess all-cause mortality: a prospective cohort study.

Authors:  Oliver Weingärtner; Dieter Lütjohann; Sven Meyer; Arne Fuhrmann; Bodo Cremers; Sarah Seiler-Mußler; Hans-F Schött; Anja Kerksiek; Silvia Friedrichs; Ursula Ulbricht; Adam Zawada; Ulrich Laufs; P Christian Schulze; Bruno Scheller; Danilo Fliser; Michael Böhm; Eric Sijbrands; Gunnar H Heine
Journal:  Clin Res Cardiol       Date:  2019-04-04       Impact factor: 5.460

4.  Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations.

Authors:  Niek C A van de Pas; Johan A C Rullmann; Ruud A Woutersen; Ben van Ommen; Ivonne M C M Rietjens; Albert A de Graaf
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-09       Impact factor: 2.745

5.  Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.

Authors:  Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

6.  Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study).

Authors:  Gianluca Bardini; Carlo B Giorda; Antonio E Pontiroli; Cristina Le Grazie; Carlo M Rotella
Journal:  Cardiovasc Diabetol       Date:  2010-05-21       Impact factor: 9.951

7.  Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency.

Authors:  Margus Viigimaa; Helena Vaverkova; Michel Farnier; Maurizio Averna; Luc Missault; Mary E Hanson; Qian Dong; Arvind Shah; Philippe Brudi
Journal:  Lipids Health Dis       Date:  2010-11-04       Impact factor: 3.876

8.  Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes.

Authors:  Carlo M Rotella; Augusto Zaninelli; Cristina Le Grazie; Mary E Hanson; Gian Franco Gensini
Journal:  Lipids Health Dis       Date:  2010-07-27       Impact factor: 3.876

9.  Glycogen storage disease type Ia: linkage of glucose, glycogen, lactic acid, triglyceride, and uric acid metabolism.

Authors:  Sakine Sever; David A Weinstein; Joseph I Wolfsdorf; Reyhan Gedik; Ernst J Schaefer
Journal:  J Clin Lipidol       Date:  2012-08-30       Impact factor: 4.766

10.  Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.

Authors:  Nuntakorn Thongtang; Jianxin Lin; Ernst J Schaefer; Robert S Lowe; Joanne E Tomassini; Arvind K Shah; Andrew M Tershakovec
Journal:  Atherosclerosis       Date:  2012-09-13       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.